TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from ANGLE plc ( (GB:CLBX) ) is now available.
CelLBxHealth plc has announced a collaboration and co-marketing agreement with QIAGEN Manchester Ltd. to advance CTC-based research. This partnership will combine CelLBxHealth’s Parsortix platform with QIAGEN’s molecular technologies to enhance drug development programs, biomarker discovery, and companion diagnostic feasibility studies. The agreement allows QIAGEN to offer the Parsortix platform to its pharmaceutical partners, potentially accelerating the adoption of liquid biopsy-based approaches in oncology drug development. This collaboration aligns with CelLBxHealth’s strategy to broaden access to its CTC technology and expand its role in precision medicine.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on GB:CLBX Stock
According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Neutral.
ANGLE plc’s overall stock score is primarily impacted by its poor financial performance and valuation, indicating significant challenges. Technical analysis also suggests bearish momentum. While the earnings call highlighted some positive developments, the need for additional funding and adverse market conditions weigh heavily on the stock’s outlook.
To see Spark’s full report on GB:CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc is a global precision CTC intelligence company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology. The company’s patent-protected Parsortix® platform is designed to harvest CTCs from blood and integrate with existing laboratory instruments for comprehensive downstream analysis, including whole-cell imaging, proteomic profiling, and full genomic workflows. CelLBxHealth focuses on product sales, lab-developed tests, and laboratory services, with commercial activities centered on accelerating the adoption of the Parsortix platform and providing clinical trial support and assay development.
Average Trading Volume: 2,791,811
Technical Sentiment Signal: Sell
Current Market Cap: £5.64M
Learn more about CLBX stock on TipRanks’ Stock Analysis page.